Items Tagged ‘AM0010’

July 11th, 2017

Clinical Data on Immunotherapy AM0010 in Advanced Pancreatic Cancer Promising

By

ARMO BioSciences, Inc., a late-stage immuno-oncology company, announced clinical data on its lead investigational immuno-oncology drug AM0010 (pegilodecakin, PEGylated Interleukin-10) at the ESMO 19th World Congress on Gastrointestinal Cancer, taking place June 28 through July 1, 2017 in Barcelona, Spain. AM0010 is being evaluated in an ongoing Phase 1/1b clinical trial that has enrolled 352 advanced cancer patients and in a […]

View full entry

Tags: AM0010, immunotherapy, Interleukin-10, News, Pancreatic Cancer, pegilodecakin